Bile acids mainly modulate inflammation and lipid and glucose metabolism through liver FXR and G protein-coupled bile acid receptor 1 (GPBAR1), especially VLDL and triglyceride production, de novo fatty acid synthesis and IR, ultimately regulating the progression of CVD in NAFLD patients (120). This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.